Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valder R Arruda

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 30, 2017
A Novel Platform for Immune Tolerance Induction in Hemophilia A MiceSimone Merlin, Elvira Stefania Cannizzo, Ester Borroni, et al.
Thrombosis and Haemostasis|June 30, 2006
Early in vivo anticoagulation inhibits the angiogenic response following hindlimb ischemia in a rodent modelErich V De Paula, Mariane C F Nascimento, Celso D Ramos, et al.
Blood|May 16, 2014
Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune responseMargareth C Ozelo, Barbara Vidal, Christine Brown, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 18, 2010
Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectorsDenise E Sabatino, Amy M Lange, Ekaterina S Altynova, et al.
Human Gene Therapy|August 7, 2002
Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapyRoland W Herzog, Paul A Fields, Valder R Arruda, et al.
Journal of Thrombosis and Haemostasis : JTH|February 26, 2021
Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-PaduaMary M Robinson, Lindsey A George, Marcus E Carr, et al.
Molecular Therapy. Methods & Clinical Development|February 20, 2024
AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of lifeBhavya S Doshi, Benjamin J Samelson-Jones, Timothy C Nichols, et al.
Blood|November 26, 2010
Assessing the potential for AAV vector genotoxicity in a murine modelHojun Li, Nirav Malani, Shari R Hamilton, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 11, 2006
Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia BHaiyan Jiang, Glenn F Pierce, Margareth C Ozelo, et al.
Blood|April 4, 2002
Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapyJane D Mount, Roland W Herzog, D Michael Tillson, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 30, 2017
A Novel Platform for Immune Tolerance Induction in Hemophilia A MiceSimone Merlin, Elvira Stefania Cannizzo, Ester Borroni, et al.
Thrombosis and Haemostasis|June 30, 2006
Early in vivo anticoagulation inhibits the angiogenic response following hindlimb ischemia in a rodent modelErich V De Paula, Mariane C F Nascimento, Celso D Ramos, et al.
Blood|May 16, 2014
Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune responseMargareth C Ozelo, Barbara Vidal, Christine Brown, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 18, 2010
Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectorsDenise E Sabatino, Amy M Lange, Ekaterina S Altynova, et al.
Human Gene Therapy|August 7, 2002
Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapyRoland W Herzog, Paul A Fields, Valder R Arruda, et al.
Journal of Thrombosis and Haemostasis : JTH|February 26, 2021
Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-PaduaMary M Robinson, Lindsey A George, Marcus E Carr, et al.
Molecular Therapy. Methods & Clinical Development|February 20, 2024
AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of lifeBhavya S Doshi, Benjamin J Samelson-Jones, Timothy C Nichols, et al.
Blood|November 26, 2010
Assessing the potential for AAV vector genotoxicity in a murine modelHojun Li, Nirav Malani, Shari R Hamilton, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 11, 2006
Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia BHaiyan Jiang, Glenn F Pierce, Margareth C Ozelo, et al.
Blood|April 4, 2002
Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapyJane D Mount, Roland W Herzog, D Michael Tillson, et al.
Pageof 9